AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 141 min read$ARQT

Burnett Patrick sold $395K of ARQT

Burnett Patrick (See Remarks) sold 15,000 shares of Arcutis Biotherapeutics, Inc. (ARQT) at an average of $26.33 ($26.08–$26.52, $0.39M total) across 2 trades over 2026-08-11 to 2026-08-12.

Original reporting
SEC EDGAR · Burnett Patrick
Published Aug 14, 2026, 12:06 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 12:34 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ARQT
Neutral
high confidence
Mentioned
$ARQT
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The newest disclosed fact is the officer’s open-market sale details and post-transaction holdings. The text does not include any new company guidance, trial results, regulatory actions, or deal activity.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no fundamental catalyst in the filing text.

03

What to watch

No context is provided on total compensation, tax obligations, or whether other insiders sold/bought around the same time, limiting inference from the transaction alone.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-13 after trades on 2026-08-11 to 2026-08-12

Background

The article is a SEC Form 4 insider transaction disclosure for Arcutis Biotherapeutics, Inc. (ARQT).

Company-level read

Ticker impact

$ARQTNeutralHigh confidence
Context

Arcutis Biotherapeutics Form 4 shows officer Burnett Patrick sold 15,000 shares in open-market trades at about $26.08 to $26.52.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan stated and no accompanying operational or guidance change in the text.

Market effects

Sector

Minimal. Insider selling in a single biotech name does not establish a sector-wide signal from the provided text.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be driven by personal liquidity needs rather than negative expectations, especially since the trades are spread across two days.

Key entities

  • issuer
    Arcutis Biotherapeutics, Inc.

    US-listed biotech company subject of the Form 4 insider sale disclosure.

  • insider
    Burnett Patrick

    Officer who sold 15,000 ARQT shares across two open-market trades.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARQT insider trading history →

Related articles

AUG 5
$ARQTHigh

Arcutis Biotherapeutics, Inc. (ARQT): Results of Operations and Financial Condition

Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update • Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand grow

SEC EDGAR 8-K6 min
JUL 8
$ARQTMedAI 8/10

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Arcutis Biotherapeutics (Nasdaq: ARQT) said the FDA accepted its supplemental NDA for ZORYVE (roflumilast) cream 0.05% to expand use for mild to moderate atopic dermatitis in infants aged 3 to 24 months. The FDA set a PDUFA target action date of Feb. 23, 2027. Data cited include Phase 2 INTEGUMENT-INFANT (101 infants) and Phase 1 PK (19 infants).

manilatimes.net5 min
AUG 28
Low

DST Global Advisors Ltd sold $38.6M of CHYM (indirect holdings)

DST Global Advisors Ltd sold 1,168,667 indirectly-held shares of Chime Financial, Inc. (CHYM) at $33.04 ($38.61M total) across 7 trades on 2026-08-26. Filed jointly with DST Global VI, L.P. (10% owner), DST Global VII, L.P. (10% owner), DST Investments XXI, L.P. (10% owner), DSTG VI Investments, L.P. (10% owner), DSTG VI Investments-A, L.P. (10% owner), DSTG VII Investments-1, L.P. (10% owner), DSTG VII Investments-4, L.P. (10% owner), DST Managers VI Ltd (10% owner) and DST Managers VII Ltd (10% owner).

SEC EDGAR1 min